A federal judge in Massachusetts has refused to dismiss a landmark antitrust lawsuit targeting five of America’s largest health insurers and their shared repricing vendor, Zelis Healthcare LLC. The ruling marks a significant turning point in ongoing scrutiny of how insurers manage out-of-network payments — and it could reshape an entire segment of the healthcare financial industry
Overview of the Ruling
U.S. District Court Judge Brian E. Murphy, of the District of Massachusetts, denied a motion to dismiss the lawsuit on March 30, 2026. The consolidated action brought together providers from California, New Jersey, Wisconsin, and Kansas. Judge Murphy concluded that the plaintiffs sufficiently alleged injury, having been forced to accept out-of-network reimbursements far below competitive market rates.
The case advances despite strong pushback from the defendants, signaling that courts are increasingly willing to scrutinize the role of repricing intermediaries in healthcare payment systems.
Who Is Zelis Healthcare?
A Powerful Middleman in Healthcare Payments
Zelis is a company that works between health insurers and healthcare providers. It calls itself a “healthcare financial experience” optimizer, with a stated goal of helping insurers lower what they pay for claims using tools like “repricing” and “claims negotiation.”
Zelis also processes payments from insurers to providers — meaning it controls both the amount and the movement of money. The company is backed by private equity firms and has grown quickly by acquiring other companies in the same space. It works with hundreds of insurers, including many of the largest ones in the United States.
Crucially, providers never choose to work with Zelis. Insurers select the vendor unilaterally, leaving out-of-network doctors and dentists with little recourse.
How the Repricing Scheme Allegedly Worked
Coordinated Price Suppression at Scale
The lawsuit alleges that the insurers — Aetna, Cigna, Elevance Health, Humana, and UnitedHealth Group — used Zelis’s repricing tools to systematically lower out-of-network reimbursements. Zelis takes a percentage of the difference between what the provider charges and what the carrier actually pays. This compensation model, critics argue, gave Zelis a direct financial incentive to cut payments as deeply as possible.
The complaint also alleges that insurers shared confidential pricing data with Zelis, which the company then used to set artificially lower prices across the market. Rather than competing independently, the insurers are accused of surrendering pricing authority to a single intermediary — effectively fixing prices in unison.
According to one complaint, coordinated pricing strategies produced discounts of up to 98% off provider invoices.
Providers Bore the Brunt
Small Practices Pushed to the Edge
Providers claim Zelis’s tools forced them to accept severely reduced reimbursements, enter one-sided negotiations, or file appeals that rarely resulted in increased payments. Furthermore, the plaintiffs say out-of-network revenue was reduced by at least half for many practices, prompting some to consider shutting down entirely.
The numbers tell a stark story. The court pointed to allegations that Zelis repriced a claim from Pacific Inpatient Medical Group at a discount of 88%, which the provider said was below market prices. That figure is not an outlier — court filings allege providers faced payment amounts as low as 1% of their invoiced charges.
No Real Alternatives for Providers
Doctors and dentists have no say in whether Zelis is used. In most cases, the repriced amount is presented on a take-it-or-leave-it basis, with appeals often resulting in delayed payment or an even lower amount. Moreover, balance billing patients is largely off the table. The No Surprises Act, which took effect in January 2022, bans balance billing for emergency services and certain non-emergency care at in-network facilities — reinforcing the providers’ legal position.
Insurers’ Defense Falls Flat
Court Rejects Cost-Savings Argument
The insurers mounted two main defenses. First, they argued that providers could have negotiated higher rates directly. Second, they contended that Zelis’s services ultimately lowered costs for policyholders. The Massachusetts court rejected both, finding that lower prices for policyholders do not justify price-fixing agreements.
Judge Murphy ruled that the providers adequately alleged the “rim” of their alleged hub-and-spoke conspiracy through circumstantial evidence, with Zelis serving as the hub that coordinated communication among competitor insurers.
Meanwhile, a Zelis spokesperson maintained that the ruling was procedural and does not change the company’s position, reiterating its commitment to transparency and full legal compliance.
Parallel Cases Signal a Wider Problem
MultiPlan Faces Similar Scrutiny
This lawsuit does not exist in isolation. The case mirrors a parallel and larger antitrust lawsuit against MultiPlan Inc., another repricing company, currently pending in the Northern District of Illinois. While MultiPlan has moved to dismiss those cases, the legal questions raised are strikingly similar — namely, whether repricers and payers are unlawfully suppressing market rates through coordinated strategies.
Together, these cases suggest a systemic issue with how third-party repricing companies operate within the U.S. healthcare payment ecosystem.
What This Means for the Industry
The ruling carries consequences well beyond the courtroom. If courts ultimately find that the repricing model constitutes price-fixing, the entire third-party repricing industry may need to restructure. Insurers that rely on vendors like Zelis to manage out-of-network costs could face regulatory and legal exposure on multiple fronts.
For providers, the case offers a rare moment of legal traction in a system that has long favored payers. For patients, the outcome could determine whether out-of-network care remains a viable option — or becomes increasingly inaccessible as providers exit the market.
As the litigation moves forward, all stakeholders in the healthcare financial ecosystem are watching closely.
